Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Prepaid Assets (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Prepaid Assets for 8 consecutive years, with $45000.0 as the latest value for Q4 2025.

  • Quarterly Prepaid Assets fell 87.8% to $45000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45000.0 through Dec 2025, down 87.8% year-over-year, with the annual reading at $45000.0 for FY2025, 87.8% down from the prior year.
  • Prepaid Assets for Q4 2025 was $45000.0 at Precision Biosciences, down from $848000.0 in the prior quarter.
  • The five-year high for Prepaid Assets was $21.2 million in Q3 2021, with the low at $35000.0 in Q1 2021.
  • Average Prepaid Assets over 5 years is $4.9 million, with a median of $1.3 million recorded in 2023.
  • The sharpest move saw Prepaid Assets plummeted 99.55% in 2021, then soared 2530.29% in 2023.
  • Over 5 years, Prepaid Assets stood at $17.4 million in 2021, then crashed by 65.44% to $6.0 million in 2022, then crashed by 93.05% to $419000.0 in 2023, then decreased by 11.93% to $369000.0 in 2024, then tumbled by 87.8% to $45000.0 in 2025.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $45000.0, $848000.0, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.